
- /
- Supported exchanges
- / F
Orexo AB (publ) (C5G F) stock market data APIs
Orexo AB (publ) Financial Data Overview
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Orexo AB (publ) data using free add-ons & libraries
Get Orexo AB (publ) Fundamental Data
Orexo AB (publ) Fundamental data includes:
- Net Revenue: 596 M
- EBITDA: 67 800 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Orexo AB (publ) News

Orexo's patent win for ZUBSOLV® appealed
UPPSALA, Sweden, July 24, 2023 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc.,...


Orexo Q2 2023 Interim Report
UPPSALA, Sweden, July 18, 2023 /PRNewswire/ -- The patent win critical enabler for future growth Q2 2023 highlights › Total net revenues of SEK 157.7 m (147.8) › EBITDA of SEK 5....

Orexo wins patent litigation for ZUBSOLV® in the US
The court found Orexo´s patents valid and infringed by Sun The outcome once again confirms the strength of the company´s intellectual property rights and the ability to develop innovative products ...

Life Science Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the lead...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.